Literature DB >> 1535691

Agonist/antagonist interactions with cloned human 5-HT1A receptors: variations in intrinsic activity studied in transfected HeLa cells.

H W Boddeke1, A Fargin, J R Raymond, P Schoeffter, D Hoyer.   

Abstract

The characteristics of 5-HT1A-recognition sites and receptor-mediated release of intracellular calcium were established in two transfected HeLa cell lines (HA 6 and HA 7) expressing different levels of human 5-HT1A receptors (about 3000 and 500 fmol/mg protein, Fargin et al. 1989; 1991; Raymond et al. 1989). The pharmacological profiles of the binding (determined with [3H]8-OH-DPAT) and the calcium response (measured using Fura-2) were clearly of the 5-HT1A type. Compounds such as 5-HT, 5-CT and 8-OH-DPAT acted as full agonists on the calcium response in both HeLa cell lines. In addition, methiothepin, pindolol, NAN 190 and SDZ 216-525 (Seiler et al. 1991) acted as silent and potent antagonists. Marked differences were observed in the responses mediated in the two cell lines. EC50 values of agonists (particularly 5-HT, 5-CT, flesinoxan and 8-OH-DPAT) were higher in HA 7 cells (up to 80-fold) than in other 5-HT1A receptor models (e.g. inhibition of adenylate cyclase in calf hippocampus). Further, a variety of compounds (ipsapirone, buspirone, spiroxatrine, MDL 73005) acted as agonists in HA 6 cells, whereas they behaved as silent antagonists in HA 7 cells (which express fewer receptors). By contrast, KB values for antagonists were comparable in HA 6 and HA 7 cells. The present data show that EC50 values and intrinsic activity for a given drug are subject to large variations depending on the number of receptors expressed in the target tissue.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1535691     DOI: 10.1007/bf00168684

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  38 in total

1.  MDL 73005EF: partial agonist at the 5-HT1A receptor negatively linked to adenylate cyclase.

Authors:  L J Cornfield; D L Nelson; E W Taylor; A R Martin
Journal:  Eur J Pharmacol       Date:  1989-12-07       Impact factor: 4.432

2.  [3H]spiroxatrine: a 5-HT1A radioligand with agonist binding properties.

Authors:  K Herrick-Davis; M Titeler
Journal:  J Neurochem       Date:  1988-02       Impact factor: 5.372

3.  Short-term regulation of Na+/K+ adenosine triphosphatase by recombinant human serotonin 5-HT1A receptor expressed in HeLa cells.

Authors:  J P Middleton; J R Raymond; A R Whorton; V W Dennis
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

4.  The human 5-HT1A receptor expressed in HeLa cells stimulates sodium-dependent phosphate uptake via protein kinase C.

Authors:  J R Raymond; A Fargin; J P Middleton; J M Graff; D M Haupt; M G Caron; R J Lefkowitz; V W Dennis
Journal:  J Biol Chem       Date:  1989-12-25       Impact factor: 5.157

5.  NAN-190: agonist and antagonist interactions with brain 5-HT1A receptors.

Authors:  L Rydelek-Fitzgerald; M Teitler; P W Fletcher; A M Ismaiel; R A Glennon
Journal:  Brain Res       Date:  1990-11-05       Impact factor: 3.252

6.  Piperazine derivatives including the putative anxiolytic drugs, buspirone and ipsapirone, are agonists at 5-HT1A receptors negatively coupled with adenylate cyclase in hippocampal neurons.

Authors:  J Bockaert; A Dumuis; R Bouhelal; M Sebben; R N Cory
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-05       Impact factor: 3.000

7.  Protein kinase C induces phosphorylation and desensitization of the human 5-HT1A receptor.

Authors:  J R Raymond
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

8.  Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist?

Authors:  P Schoeffter; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-06       Impact factor: 3.000

9.  Mixed agonist/antagonist properties of NAN-190 at 5-HT1A receptors: behavioural and in vivo brain microdialysis studies.

Authors:  S Hjorth; T Sharp
Journal:  Life Sci       Date:  1990       Impact factor: 5.037

10.  Further investigation of the in vivo pharmacological properties of the putative 5-HT1A antagonist, BMY 7378.

Authors:  T Sharp; L I Backus; S Hjorth; S R Bramwell; D G Grahame-Smith
Journal:  Eur J Pharmacol       Date:  1990-02-13       Impact factor: 4.432

View more
  23 in total

Review 1.  The recombinant 5-HT1A receptor: G protein coupling and signalling pathways.

Authors:  J R Raymond; Y V Mukhin; T W Gettys; M N Garnovskaya
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D₂ and D₃ Receptors.

Authors:  Maarten E A Reith; Aloke K Dutta; Dana E Selley; Juan Zhen; Tamara Antonio; Joanna C Jacob; David K Grandy
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

3.  A receptor autoradiographic and in situ hybridization analysis of the distribution of the 5-ht7 receptor in rat brain.

Authors:  E L Gustafson; M M Durkin; J A Bard; J Zgombick; T A Branchek
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

4.  Pharmacological characterizations of recombinant human 5-HT1D alpha and 5-HT1D beta receptor subtypes coupled to adenylate cyclase inhibition in clonal cell lines: apparent differences in drug intrinsic efficacies between human 5-HT1D subtypes.

Authors:  J M Zgombick; L E Schechter; N Adham; S A Kucharewicz; R L Weinshank; T A Branchek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

5.  (-)Tertatolol is a potent antagonist at pre- and postsynaptic serotonin 5-HT1A receptors in the rat brain.

Authors:  T Jolas; S Haj-Dahmane; L Lanfumey; C M Fattaccini; E J Kidd; J Adrien; H Gozlan; B Guardiola-Lemaitre; M Hamon
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-05       Impact factor: 3.000

6.  The novel 5-HT1A receptor antagonist, SDZ 216-525, decreases 5-HT release in rat hippocampus in vivo.

Authors:  T Sharp; R McQuade; J R Fozard; D Hoyer
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

7.  GH4ZD10 cells expressing rat 5-HT1A receptors coupled to adenylyl cyclase are a model for the postsynaptic receptors in the rat hippocampus.

Authors:  C J Fowler; P C Ahlgren; G Brännström
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

8.  Towards a quantitative representation of the cell signaling mechanisms of hallucinogens: measurement and mathematical modeling of 5-HT1A and 5-HT2A receptor-mediated ERK1/2 activation.

Authors:  Chiung-Wen Chang; Ethan Poteet; John A Schetz; Zeynep H Gümüş; Harel Weinstein
Journal:  Neuropharmacology       Date:  2008-08-13       Impact factor: 5.250

9.  Intracellular cross-talk between receptors coupled to phospholipase C via pertussis toxin-sensitive and insensitive G-proteins in DDT1MF-2 cells.

Authors:  J M Dickenson; S J Hill
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

10.  A 5-HT7 heteroreceptor-mediated inhibition of [3H]serotonin release in raphe nuclei slices of the rat: evidence for a serotonergic-glutamatergic interaction.

Authors:  Laszlo G Harsing; Ibolya Prauda; Jozsef Barkoczy; Peter Matyus; Zsolt Juranyi
Journal:  Neurochem Res       Date:  2004-08       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.